期刊文献+

局部晚期非小细胞肺癌时辰放疗的临床研究 被引量:5

下载PDF
导出
摘要 目的对肺癌晚期局部非小细胞时辰放疗的临床效果进行分析和研究。方法选择本单位自2010年1月至2012年1月收治的80例临床证实为非小细胞肺癌晚期的患者作为研究对象,对患者进行随机分组,分别为放疗组及时辰组,每组各40例患者,两组患者根据三维造形计划设计放疗方案,两组患者均采用西门子直线加速器进行放疗,常规放疗组放疗时间为每天早上8点至中午12点,时辰组患者放疗时间为下午6点至晚上10点,观察两组患者临床治疗的效果。结果放疗组患者癌细胞消退率为45%,时辰组癌细胞消退率为65%。,两组患者存在统计学差异(P<0.05),放疗组出现急性反应共有13例,急性反应率为100%,时辰组出现急性反应为0例,急性反应率为0,两者存在显著的差异性(P<0.05)。结论时辰放疗对人体的副作用较常规放疗的副作用小,缓解率高,与常规放疗比较,临床疗效更加让人满意。
作者 史玉树
出处 《中国实用医药》 2012年第26期100-101,共2页 China Practical Medicine
  • 相关文献

参考文献2

二级参考文献18

  • 1Movsas B. Innovative treatment strategies in locally advanced and/or un-resectable non-small cell lung cancer[J]. Cancer Control, 2000, 7(1):25-34.
  • 2Sim S, Rosenzweig KE, Schindelheim R, et al. Induction chemotherapy plus three-dimensional conformal radiation therapy in the definitive treatment of locally advanced non-small-cell lung cancer [J]. Int J Radiat Oncol Biol Phys, 2001, 5(13):660-665.
  • 3Fu XL, Huang H, Bentel G, et al. Predicting the risk of symptomatic radiation-induced lung injury using both the physical and biologic parameters and transforming growth factor[J].Int J Radlat Oncol Biol Phys, 2001, 50(4):899- 908.
  • 4Lee SW, Choi EK, Lee JS, et al. Phase Ⅱ study of three- dimensional conformal radiotherapy and concurrent mitomycin-C,vinblastine,an cisplatin chemotherapy for stage Ⅲ locally advanced,unresectable, non-small-cell lung cancer[J]. Int J Radiat Oncol Biol Phys, 2003, 56(4):996- 1004.
  • 5Rusu P, Ciuleanu TE, Cernea D, et al. Concurrent ehemoradiotherapy with vinorelbine and-a platinum compound followed by consolidation chemotherapy for unreseetable stage Ⅲ NSCLC: preliminary results of a phase Ⅱ study[J]. J Buon, 2007, 12(1):33-39.
  • 6Price A, Ironside JAD, Litde FA, et al. A phase Ⅰ study of weekly low dose gemeitabine (G) and cisplatin (P) with involved field radiotherapy (RT) in stage Ⅱ b-Ⅲ non- small cell lung eancer(NSCLC)[J]. ESTRO, 2004, 23:352.
  • 7Nakano K, Yamamoto M, Iwamoto H, et al. Daily low-dose cisplatin plus concurrent high-dose thoracic radiotherapy in elderly patients with locally advanced unresectable non-small-cell lung cancer [J]. Gan To Kagaku Ryoho, 2003, 30(9):1283-1287.
  • 8Semrau S, Bier A, Thierbach U, et al. Concurrent radiochemotherapy with vinorelbine plus cisplatin or carboplatin in patients with locally advanced non-small-cell lung cancer (NSCIC) and an increased risk of treatment complications. Preliminary results [J]. Strahlenther Onkol, 2003, 179(12):823-831.
  • 9Gandara DR, Chansky K, Albain KS, et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage ⅢB non-small-cell lung cancer:phase Ⅱ Southwest Oncology Group Study S9504[J]. J Clin Oncol, 2003, 21(10):2004- 2010.
  • 10Sakai H, Yoneda S, Kobayashi K, et al. Phase Ⅱ study of hi-weekly docetaxel and carboplatin with concurrent thoracic radiation therapy followed by consolidation ehemotherapy with doeetaxel plus carboplatin for stage Ⅲ unreseetable non-small cell lung cancer [J]. Lung Cancer, 2004, 43(2): 195-201.

同被引文献80

引证文献5

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部